PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
EBIT growth of 16.52% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
16.52%
Operating income growth of 16.52% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
16.61%
Net income growth of 16.61% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
17.14%
EPS growth of 17.14% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
17.14%
Diluted EPS growth of 17.14% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Healthcare median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
9.84%
Positive OCF growth while Healthcare median is negative. Peter Lynch might see a strong relative advantage in operational efficiency.
13.18%
Positive FCF growth while Healthcare median is negative. Peter Lynch might view this as a notable advantage over peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
90.48%
OCF/share CAGR of 90.48% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
83.42%
3Y OCF/share growth of 83.42% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-2587.91%
Negative 10Y net income/share CAGR vs. Healthcare median of 15.18%. Seth Klarman might see a fundamental problem if peers maintain growth.
90.30%
5Y net income/share CAGR > 1.5x Healthcare median of 19.29%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
86.48%
3Y net income/share CAGR > 1.5x Healthcare median of 9.02%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
1551.35%
Equity/share CAGR exceeding 1.5x Healthcare median of 20.78% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-71.69%
Negative 5Y equity/share growth while Healthcare median is 19.83%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-47.82%
Negative 3Y equity/share growth while Healthcare median is 12.14%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth of 13.10% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
15.36%
BV/share growth of 15.36% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-14.09%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-7.82%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-4.34%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.